Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

Blood cancers such as leukaemia and lymphoma
Inherited genetic disorders including thalassemia and sickle cell disease
Neurological conditions such as cerebral palsy and brain injury
Immune deficiencies and metabolic disorders
Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

Cerebral Palsy
Thalassemia
Leukaemia
HSV Encephalitis
Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

Families gain access to 1,000,000+ stored cord blood units across the network
Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

Order now Find out more

FamiCord Group releases

Patients

7800+

Expand table
No.	Source	Source type	Diagnosis	Medical sector	Year of application	Therapy	Country	Age of the recipient
8101	Cord Tissue	Allogeneic – Unrelated	Spinocerebellar Ataxia	Neurology	2015	Experimental Therapy	Poland	44,6
8102	Cord Tissue	Allogeneic – Unrelated	Spinocerebellar Ataxia	Neurology	2015	Experimental Therapy	Poland	24,3
8103	Cord Tissue	Allogeneic – Unrelated	Stroke	Neurology	2015	Experimental Therapy	Poland	62,8
8104	Cord Tissue	Allogeneic – Unrelated	Stroke	Neurology	2015	Experimental Therapy	Poland	54,9
8105	Cord Tissue	Allogeneic – Unrelated	Traumatic Encephalopathy	Neurology	2015	Experimental Therapy	Poland	20,11
8106	Cord Blood	Allogeneic – Related	Acute Lymphoblastic Leukemia	Hematology	2015	Standard Therapy	Poland	4
8107	Cord Blood	Autologous	Brain Damage	Neurology	2015	Experimental Therapy	Germany	5
8108	Cord Blood	Autologous	Hypoxia-Ischemic Encephalopathy (Hie)	Neurology	2015	Experimental Therapy	UK	6 months
8109	Cord Blood	Autologous	Neuroblastoma	Hematology	2015	Standard Therapy	Germany	5
8110	Cord Blood	Allogeneic – Related	Scid (Severe Combined Immunodeficiency)	Hematology	2015	Standard Therapy	UK	3 months
8111	Cord Blood	Allogeneic – Related	Sickle Cell Anemia	Hematology	2015	Standard Therapy	UK	2,6
8112	Cord Blood	Allogeneic – Related	Thalassemia	Hematology	2015	Standard Therapy	UK	12
8113	Cord Blood	Allogeneic – Related	Thalassemia Major	Hematology	2015	Standard Therapy	Turkey	3
8114	Cord Blood	Allogeneic – Related	Thalassemia Major	Hematology	2015	Standard Therapy	Turkey	2
8115	Bone Marrow Family	Allogeneic	Chronic Lymphocytic Leukemia	Hematology	2015	Standard Therapy	Germany	74
8116	Bone Marrow Family	Allogeneic	Secondary Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	64
8117	Apheresis	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2015	Standard Therapy	Germany	23
8118	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	72
8119	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	43
8120	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	63
8121	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	73
8122	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	61
8123	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	33
8124	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	42
8125	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	57
8126	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	37
8127	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	72
8128	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	63
8129	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	66
8130	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	45
8131	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	48
8132	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	59
8133	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2015	Standard Therapy	Germany	58
8134	Apheresis	Autologous	Anaplastic Large Cell Lymphoma	Hematology	2015	Standard Therapy	Germany	57
8135	Apheresis	Autologous	Anaplastic T-Cell Lymphoma – Relapse	Hematology	2015	Standard Therapy	Germany	26
8136	Apheresis	Allogeneic	Aplastic Anemia – Relapse	Hematology	2015	Standard Therapy	Germany	53
8137	Apheresis	Allogeneic	B-Cell Non-Hodgkin Lymphoma	Hematology	2015	Standard Therapy	Germany	59
8138	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma	Hematology	2015	Standard Therapy	Germany	48
8139	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma	Hematology	2015	Standard Therapy	Germany	23
8140	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma	Hematology	2015	Standard Therapy	Germany	62
8141	Apheresis	Allogeneic	Chronic Lymphocytic Leukemia	Hematology	2015	Standard Therapy	Germany	51
8142	Apheresis	Allogeneic	Chronic Myelogenous Leukemia	Hematology	2015	Standard Therapy	Germany	50
8143	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2015	Standard Therapy	Germany	31
8144	Apheresis	Autologous	Diffuse Large B-Cell Lymphoma	Hematology	2015	Standard Therapy	Germany	57
8145	Apheresis	Autologous	Ewing Sarcoma	Hematology	2015	Standard Therapy	Germany	24
8146	Apheresis	Autologous	Germ Cell Tumor	Hematology	2015	Standard Therapy	Germany	17
8147	Apheresis	Autologous	Gray Zone Lymphoma	Hematology	2015	Standard Therapy	Germany	26
8148	Apheresis	Autologous	Hodgkin Relapse	Hematology	2015	Standard Therapy	Germany	29
8149	Apheresis	Autologous	Lymphoma	Hematology	2015	Standard Therapy	Germany	53
8150	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2015	Standard Therapy	Germany	56
8151	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2015	Standard Therapy	Germany	66
8152	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2015	Standard Therapy	Germany	53
8153	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2015	Standard Therapy	Germany	63
8154	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2015	Standard Therapy	Germany	58
8155	Apheresis	Autologous	Mantle Cell Lymphoma-Relapse	Hematology	2015	Standard Therapy	Germany	66
8156	Apheresis	Allogeneic	Morbus Hodgkin	Hematology	2015	Standard Therapy	Germany	25
8157	Apheresis	Allogeneic	Morbus Hodgkin	Hematology	2015	Standard Therapy	Germany	22
8158	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	58
8159	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	54
8160	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	62
8161	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	70
8162	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	69
8163	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	56
8164	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	75
8165	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	70
8166	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	60
8167	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	72
8168	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	56
8169	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	65
8170	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	37
8171	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	54
8172	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	29
8173	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	68
8174	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	50
8175	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	61
8176	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	69
8177	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	60
8178	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	72
8179	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	43
8180	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	53
8181	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	73
8182	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	66
8183	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	61
8184	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	70
8185	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	71
8186	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	62
8187	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	56
8188	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	74
8189	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	50
8190	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	51
8191	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	63
8192	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	53
8193	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	72
8194	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	48
8195	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	63
8196	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	60
8197	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	65
8198	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	71
8199	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	61
8200	Apheresis	Autologous	Multiple Myeloma	Hematology	2015	Standard Therapy	Germany	61

Page 82 of 89 1 80 81 82 83 84 89

Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

100% infusion success rate

For samples released for transplant.

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

Expand table
Sample release date	Medical condition	Recipient relationship	Age of the recipient	Unit volume	Medical center	Country
2005.11	Thalassemia	Allogeneic (Sibling)	4 Years	144ml	Mount Vernon Hospital	Singapore
2005.11	Leukaemia	Allogeneic (Sibling)	Restricted	Restricted	Stem Cells and Immunology Department, Birmingham	UK
2007.02	Thalassemia	Allogeneic (Sibling)	7 Years	76ml	Kinderlink der Tu Munchen	Germany
2009.08	Cerebral Palsy	Autologous (Self)	3 Years	51ml	Duke University, North Carolina	USA
2010.01	Cerebral Palsy	Autologous (Self)	3 Years	81ml	Duke University, North Carolina	USA
2013.10	Thalassemia	Allogeneic (Sibling)	5 Years	58ml	Catherine Lewis Centre, Hammersmith	UK
2014.01	Leukaemia	Allogeneic (Sibling)	4 Years	71ml	Medizinische Hochschule, Hanover	Germany
2014.05	Cerebral Palsy	Autologous (Self)	1 year	68ml	Duke University, North Carolina	USA
2014.06	HSV Encephalitis & NMDA Receptor Antibody Virus	Autologous (Self)	2 Years	57ml	Duke University, North Carolina	USA
2014.08	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	3 Months	39ml	Duke University, North Carolina	USA
2015.02	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	6 Months	53ml	Duke University, North Carolina	USA
2015.03	Severe Combined Immune Deficiency	Autologous (Self)	3 Months	74ml	Duke University, North Carolina	USA
2015.03	Sickle Cell Disease	Allogeneic (Sibling)	2 .5 Years	57ml	BLK Hospital, New Delhi	India
2015.11	Thalassemia	Allogeneic (Sibling)	12 Years	87ml	Children’s Hospital of Pittsburgh of UPMC	USA
2016.03	Cerebral Palsy	Allogeneic (Sibling)	6 Years	101ml	Duke University, North Carolina	USA
2017.04	Lymphoblastic Leukaemia (^1)	N/A (Identical twin girls)	Restricted	125ml	Bambin Gesu Childrens’ Hospital, Rome	Italy
2017.06	Cerebral Palsy	Autologous (Self)	7 Years	82ml	Duke University, North Carolina	USA
2017.06	Cerebral Palsy	Autologous (Self)	3.4 Years	132ml	Duke University, North Carolina	USA
2018.03	Autism	Autologous (Self)	5.4 Years	73ml	Duke University, North Carolina	USA
2018.03	Cerebral Palsy	Autologous (Self)	3.4 years	132ml	Duke University, North Carolina	USA
2019.06	Cerebral Palsy	Allogeneic (Sibling)	3 Years	104ml	Duke University, North Carolina	USA
2022.02	Cerebral Palsy	Allogeneic (Sibling)	11 Years	185ml	Duke University, North Carolina	USA
2023.08	Cerebral Palsy	Allogeneic (Sibling)	3 Years	46ml	Duke University, North Carolina	USA
2024.01	Thalassaemia	Allogeneic (Sibling)	8 Years	45ml	Cincinnati Children’s Hospital Medical Center	USA